explore -WSS

explore

author：entertainment 2025-09-30 12:56:59 - browse：83

Obesity conference attendees with a pink and blue Wegovy sign hanging from the ceiling above. -- obesity coverage from STAT — Wegovy, the obesity drug, was inescapable at the ObesityWeek conference in Dallas. Elaine Chen

DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and Eli Lilly are displaying more than a dozen studies that together carry the message: Our blockbuster weight loss treatments will be worth it for society.

But experts point out that much of this company-funded research does not include the cost of the drugs themselves, which sell at more than $10,000 per year in the U.S. and are meant to be taken indefinitely.

The two major pharmaceutical companies have seen interest skyrocket for their GLP-1-based drugs like Ozempic, Wegovy, and Mounjaro, a new generation of medications that can cut substantial amounts of weight. But insurance plans have been slow to grant wide access to obesity treatments, concerned that the vast amount of people eligible to take them, along with their high price, could lead to significant financial strain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Fed up with FDA, ALS advocates consider a take

focus

WSS

Mass General totes up its waste in a move to tackle climate change

Eli Lilly CEO gives to Mike Pence presidential super PAC

Tesla recalling nearly 16,000 of its 2021

The struggle to figure out which patients 'deserve' Wegovy

EF3 tornado rips through North Carolina amid extreme weather nationwide

Chamber of Commerce, DOJ clash in court over drug prices

hotspot

explore

leisure time

How one medical school became remarkably diverse

Affordable Connectivity Program vital to health care, experts say

Trump demands the U.S. pay no more for drugs than other countries … again

How the messy conversation about Dolly changed bioethics

23andMe had bad news about my health. I wish a person had delivered it

PBMs drew scrutiny in House hearing — and so did pharma

State Dept. review finds Biden bears some blame for Afghanistan failures

Texas Department of Public Safety speaks out on migrant abuse allegations

Virginia high school admissions case could be legal follow

Vir antibody drug aimed at influenza A fails in clinical trial

focus

Stanford president's case begs question: Who takes blame?

FDA weighs limits of animal data in assessing artificial wombs

How the messy conversation about Dolly changed bioethics

Ending racial health disparities hinges on penalties, political will

Winning ticket for $1 billion Powerball jackpot sold in California

Neurocrine congenital adrenal hyperplasia trial succeeds

Wikipedia

Wikipedia

focus

focus